Pacira Biosciences, Inc.
Case Overview
56 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 03/17/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Pacira Biosciences, Inc. |
Court: | Court: District of New Jersey |
Case Number: | Case Number: 2:25cv00322 |
Class Period: | Class Period: 08/02/2023 - 08/08/2024 |
Ticker: | Ticker: PCRX |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for New Jersey on behalf of those who acquired Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ:PCRX) securities during the period from August 2, 2023, through August 8, 2024 (“the Class Period”). Investors have until March 14, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On August 9, 2025, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement. Pacira disclosed that the court “found that the company’s U.S. Patent No. 11,033,495 (the ‘495 patent) is not valid,” and thus, eVenus is not infringing on anything. Pacira’s 495 is for Exparel, which is the main source of growth for the Company, encapsulating roughly 80% of its revenue. On this news, the price of Pacira shares declined by $10.66 per share, or approximately 47.7%, from $22.36 per share on August 7, 2024, to close at $11.70 on August 8, 2024.
The complaint alleges that Defendants, throughout the Class Period, provided investors with material information about Pacira’s '495 patent validity and scope. In particular, the Company touted widespread protection of Exparel, despite the previous receipt of a negative outcome regarding claims construction in another lawsuit against eVenus involving the '495 patent, as well as Pacira '336 patent.
On August 9, 2025, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement. Pacira disclosed that the court “found that the company’s U.S. Patent No. 11,033,495 (the ‘495 patent) is not valid,” and thus, eVenus is not infringing on anything. Pacira’s 495 is for Exparel, which is the main source of growth for the Company, encapsulating roughly 80% of its revenue. On this news, the price of Pacira shares declined by $10.66 per share, or approximately 47.7%, from $22.36 per share on August 7, 2024, to close at $11.70 on August 8, 2024.
The complaint alleges that Defendants, throughout the Class Period, provided investors with material information about Pacira’s '495 patent validity and scope. In particular, the Company touted widespread protection of Exparel, despite the previous receipt of a negative outcome regarding claims construction in another lawsuit against eVenus involving the '495 patent, as well as Pacira '336 patent.